Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAD106 Extension Study in Alzheimer's Disease
NCT00956410Phase 2Completed
- Sponsor
- Novartis
- Start
- Sep 2009
- Primary completion
- Jun 2011
- Modality
- Recombinant Protein Vaccines, Peptide-based Cancer Vaccines
- Countries
- 4
01
Overview
A Phase 2 trial of amilomotide in Alzheimer's disease (AD), sponsored by Novartis. Started Sep 2009; status: completed.
02
Drugs
amilomotide
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT00956410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00956410.